Category: Research

If you have asthma that is not well controlled, you have probably seen the adverts: a short form,
a promise that researchers in your area are looking for people like you, and a request for your
phone number. Asthma is one of the most heavily recruited conditions in US clinical research, and
the recruitment industry around it is substantial.

That does not make it illegitimate. Asthma trials are real, they are common, and for some people
joining one is a reasonable decision. But the adverts are marketing, and they are not where the
decision should be made. This article covers why asthma is recruited so heavily, what joining
typically involves, and how to check that a specific study is real before you share anything.

It is information, not medical advice. MediVara does not screen, endorse or recommend
any trial or recruitment service.

Why asthma trials recruit so aggressively

Three things make asthma unusually attractive to researchers, and they explain the volume of
advertising.

The population is large. Current asthma affects around 7.7% of the US
population, so a great many people are potentially eligible for something.

A lot of it is not well controlled. Half of children with current asthma had
uncontrolled asthma, and close to four in ten adults with asthma reported an attack in 2021. Poor
control is precisely what new treatments are trying to address, so trials actively seek people whose
current regimen is not working well.

It is measurable. Lung function can be quantified, symptoms and rescue-inhaler
use can be counted, and exacerbations are countable events. Conditions that produce clean numbers
are easier to study, which means more studies get run.

The result is genuine demand for participants — and a recruitment industry built to meet
it. Both things are true at once.

What an asthma trial usually involves

Specifics vary enormously by study, and the only reliable source is the protocol for the study in
front of you. In general terms, expect:

• A screening visit before enrolment, typically including lung-function testing.
  Many people are screened and not enrolled.
• A run-in period in some studies, during which your existing treatment is
  standardised before anything changes.
• Regular visits — often more frequent than your ordinary asthma care.
• Spirometry at most visits.
• A daily diary of symptoms and rescue-inhaler use.
• Rules about your other medication, which is the part most worth understanding
  in detail before agreeing.

That last point deserves emphasis. Ask exactly what happens to your current treatment, whether
any of it is paused or replaced, and what you are to do if your asthma worsens during the study.
A trial should have a defined answer for that, and you should know it before you enrol.

The placebo question, specifically for asthma

This is the question people most want answered and most hesitate to ask.

Ask two things, separately. Is there a placebo group? And what does that group
receive? In many trials for conditions where withholding treatment would be unsafe, the
comparison group receives standard care with placebo added to it, rather than placebo instead of
treatment. That is a materially different proposition from going untreated, and the answer should
be stated plainly in the consent discussion.

Also ask what the rules are for using your rescue inhaler during the study, and what triggers the
study team to take you out of it if your asthma deteriorates.

Checking that a study is real

Many asthma trials recruit through third-party websites and ad campaigns. Some are run by
legitimate recruitment firms working for a sponsor. A polished page tells you nothing either way,
and the site is not the study.

1. Ask for the NCT number. Every registered study has one. A legitimate recruiter
   can provide it.
2. Look it up on ClinicalTrials.gov
   yourself, by typing the address rather than following a link you were sent.
3. Compare the advert against the registry record — condition, phase,
   eligibility criteria, recruiting status, sponsor and listed locations.
4. Check a site near you is genuinely recruiting.
5. Ask what happens to your data if you are screened out. A recruitment form is a
   disclosure of health information. You are entitled to know whether it is retained, shared or used
   for marketing.

Treat these as warning signs: no NCT number available on request, guaranteed acceptance, any
request for payment to participate, pressure to decide immediately, or a claim that the study will
cure your asthma. Legitimate studies do not charge participants, and research does not make
guarantees.

Our general guide to how clinical trials work, including consent, eligibility and IRB oversight,
covers the verification process in more detail.

Questions specific to an asthma study

• What is being tested, and what phase is the study?
• What happens to my current controller and reliever medication?
• Is there a placebo arm, and what does that arm receive?
• What are the rules for rescue-inhaler use during the study?
• What happens if my asthma gets worse — who do I contact, at any hour?
• How many visits, how long is each, and over what total period?
• Will I have spirometry, and will I be told my results?
• Who pays for what? Research procedures are commonly covered by the sponsor, but routine care
  may still be billed.
• Are travel and time reimbursed?
• What happens at the end — can I continue the treatment if it helped?
• Will my usual asthma clinician be informed that I am enrolled?

That last question is easy to skip and worth asking. Someone is managing your asthma; a study is
a significant change to it.

Deciding, honestly

The reasonable reasons to join are access to something not otherwise available, closer monitoring
than routine care usually provides, and contributing to knowledge that helps other people with
asthma later. All three are real.

Against that: the treatment may not work, you may be in the comparison arm, there may be unknown
side effects, and the visit schedule is usually more demanding than ordinary care. Declining a trial
is a completely reasonable decision, and being screened out is common and not a judgement about you.

Before enrolling, discuss it with the clinician who manages your asthma. They
know your control history, your current regimen and how a study’s medication rules would interact
with it — none of which a recruitment form can see.

Before you look at trials at all

If the reason you are considering a study is that your asthma is not well controlled, there are
two things worth ruling out first, because both are common and both are fixable.

Inhaler technique. More than 8 in 10 US patients with obstructive lung disease
make at least one technique error, and technique decays over time even after correct teaching. If a
share of every dose is not reaching your lungs, the medication will look less effective than it is.
This is worth checking with a pharmacist
before concluding that your treatment has failed.

Whether your plan has been reviewed recently. Asthma guidance has changed
meaningfully in recent years. A regimen that has not been revisited in a long time may not reflect
current practice, and what “controlled” should look like
is a reasonable thing to raise at your next appointment.

A clinical trial is a legitimate option. It should not be the first thing tried when simpler
explanations have not been ruled out.

Sources

• ClinicalTrials.gov — Learn About Studies
• ClinicalTrials.gov — Glossary Terms
• CDC — Most Recent Asthma Data
• Inhalation Technique Errors with Metered-Dose Inhalers: A Systematic Review and Meta-Analysis of U.S. Studies

MediVara publishes health journalism. This article is not medical advice, is not reviewed by
a licensed clinician, and MediVara does not screen, endorse or recommend any clinical trial or
recruitment service. Decisions about trial participation and about asthma treatment belong with a
qualified healthcare professional.

Frequently asked questions

Are asthma clinical trials legitimate?

Asthma trials are real and common, and asthma is one of the most heavily recruited conditions in US clinical research. That recruitment volume is driven by genuine factors: a large population, a high proportion of poorly controlled disease, and outcomes that are easy to measure. But an advert is marketing, and the site running it is not the study. Verify any specific study on ClinicalTrials.gov using its NCT number before sharing your details.

Will I be given a placebo in an asthma trial?

It depends on the study design, and you should ask two separate questions: whether there is a placebo group, and what that group actually receives. In many trials for conditions where withholding treatment would be unsafe, the comparison group receives standard care with placebo added to it rather than placebo instead of treatment. Also ask what the rules are for rescue-inhaler use and what happens if your asthma worsens during the study.

Does it cost money to join an asthma trial?

Legitimate studies do not charge participants to take part, and any request for payment is a serious warning sign. Research procedures are commonly covered by the sponsor, but routine care costs may still be billed to you or your insurer, so ask specifically who pays for what before enrolling.

What happens to my current asthma medication during a trial?

This is the part most worth understanding in detail before agreeing. Ask exactly what happens to your current controller and reliever, whether any of it is paused or replaced, what the rules are for rescue-inhaler use, and what you should do if your asthma worsens. A study should have a defined answer for each, and you should know it before you enrol.

Should I try anything else before looking at trials?

If the reason you are considering a study is poor control, two common and fixable things are worth ruling out first. The first is inhaler technique: more than 8 in 10 US patients with obstructive lung disease make at least one technique error, and technique decays over time even after correct teaching. The second is whether your treatment plan has been reviewed recently, since asthma guidance has changed meaningfully in recent years.

A test result arrives and it says something unexpected. The immediate reaction is almost always to
treat it as a fact about your body. Often it is not — or not yet. It is a probability
statement, and how likely it is to be right depends heavily on something the result itself does not
tell you: how common the condition is among people like you.

This is a companion to our guide to what preventive screening is and what it can miss. It explains why tests are wrong more often than most people expect, what overdiagnosis
means and why it is the hardest harm to see, and how to read a result without either panicking or
dismissing it.

No test is a yes-or-no machine

Every test has two ways of being wrong.

• A false positive says something is there when it is not.
• A false negative says nothing is there when something is.

These are not defects in a badly made test. They are properties of every test, because tests
measure a proxy — a chemical level, a density on an image, an electrical pattern — and
the ranges for people with and without a condition always overlap somewhat.

Two terms describe how a test handles that overlap:

• Sensitivity — how good it is at catching people who do have the
  condition. High sensitivity means few false negatives.
• Specificity — how good it is at clearing people who do not. High
  specificity means few false positives.

The two trade off against each other. A test tuned to miss almost nobody will flag more healthy
people; one tuned to avoid false alarms will miss more real cases. Where a test is set on that dial
is a deliberate design choice, not an accident.

Why a positive result on a rare condition is usually wrong

This is the part that is genuinely counter-intuitive, and it is the single most useful idea in
this article.

Imagine a test with 99% specificity — it wrongly flags only 1 in 100 healthy people. That
sounds excellent. Now apply it to 10,000 people for a condition that affects 1 in 1,000.

• About 10 people actually have the condition. A good test finds most of them — say 9.
• About 9,990 do not. One per cent of them are wrongly flagged — about 100 people.

So roughly 109 people get a positive result, and only 9 of them have the condition. More
than 90% of the positives are false — from a test that is 99% specific.

Nothing is wrong with the test. The arithmetic is driven by how rare the condition is. This is
why testing a broad, low-risk population for an uncommon condition produces a flood of false alarms,
and why the same test used in people with symptoms or known risk factors performs far better: in
that group, the condition is more common to begin with, so a positive result carries more weight.

It is also the mathematical reason screening guidelines are bounded by age and risk rather than offered to everyone.

Overdiagnosis: the harm that does not look like one

Overdiagnosis is different from a false positive, and the distinction matters.

• A false positive finds something that is not there.
• Overdiagnosis finds something that is there, correctly, but that would
  never have caused symptoms or shortened your life.

The finding is real. The biopsy confirms it. Nobody made a mistake. And yet treating it delivers
no benefit, while carrying every ordinary risk of treatment — surgery, medication, side
effects, cost, and the permanent status of being a patient.

Overdiagnosis is hard to see because it is invisible at the individual level. A person who is
overdiagnosed and treated appears to be a success story: something was found, it was treated, they
are fine. Nobody can know they would have been fine anyway. The phenomenon is only visible in
population data — when a screening programme finds far more cases than ever went on to cause
harm before screening existed.

Because you cannot tell in advance which findings would have stayed harmless, overdiagnosis is
genuinely difficult to avoid rather than simply careless. It is a real cost of screening that an
honest account has to include.

Incidental findings

Broad imaging frequently finds something unrelated to what was being looked for — a nodule,
a cyst, an anatomical variation. A minority matter. Most do not. But separating the two usually
means more scans, sometimes a biopsy, and a period of monitoring.

The clinical term for a small, probably harmless finding of uncertain significance is sometimes
half-jokingly called an incidentaloma. The joke reflects a real problem: once something is
on a record, it is difficult to leave alone, even when leaving it alone is the right answer.

Reading your own results without spiralling

A positive screening result is not a diagnosis. It is a reason to do a
diagnostic test. The screening result opens the question; something else closes it.

A normal result is reassurance, not a guarantee. False negatives exist. If a
symptom appears later, a clear test from before does not answer it — and it is not a reason
to wait.

A number outside the reference range is not automatically abnormal. Reference
ranges are usually set so that a percentage of healthy people fall outside them by definition. On a
panel of twenty measurements, at least one falling outside its range is the expected outcome, not a
surprise.

Trend usually beats a single reading. One blood pressure measurement in a
clinic is weak evidence; a series taken over time in ordinary conditions is much stronger. This is
precisely why national guidance recommends confirming raised blood pressure outside the clinical
setting before starting treatment.

Questions worth asking about any result

• Is this a screening test or a diagnostic test?
• Given my age and risk, how likely is it that this positive result is real?
• What is the next step to confirm or rule it out, and how long will it take?
• What happens if we do nothing and repeat the test later?
• If this is confirmed, does treating it change my outcome — or only my paperwork?
• Is this finding what we were looking for, or something we found along the way?

That fifth question is the one most worth asking, and the one least often asked.

What to take from this

• Every test has false positives and false negatives; this is design, not failure.
• For an uncommon condition in a low-risk population, most positive results are false —
  even from a very specific test.
• Overdiagnosis means correctly finding something that would never have harmed you, and it is
  invisible in any individual case.
• A positive screening result opens a question; a diagnostic test closes it.
• A normal result does not override a symptom that appears afterwards.
• Trends are more informative than single readings.
• Before buying a screening bundle, work through the ten questions.

Sources

• U.S. Preventive Services Task Force — A and B Recommendations
• USPSTF Recommendations for Physical Examination Procedures for Average Risk Asymptomatic Adults (NCBI Bookshelf)

MediVara publishes health journalism. This article is not medical advice and is not reviewed
by a licensed clinician. Interpreting your own test results is something to do with a qualified
healthcare professional who knows your history.

Frequently asked questions

Does a positive screening result mean I have the disease?

No. A positive screening result means your risk is higher than it was before the test, and that a diagnostic test is warranted. For an uncommon condition in a low-risk population, the majority of positive screening results turn out to be false. The screening result opens the question; a diagnostic test closes it.

Why are false positives so common?

Because of how rare the condition is, not because the test is bad. Take a test that wrongly flags only 1 percent of healthy people, applied to 10,000 people for a condition affecting 1 in 1,000. Around 10 people have it and about 9 are found. Of the 9,990 who do not, 1 percent are wrongly flagged, which is about 100 people. So roughly 109 positives appear and only 9 are real. Over 90 percent are false, from a test that is 99 percent specific.

What is overdiagnosis?

Overdiagnosis is correctly finding a real abnormality that would never have caused symptoms or shortened your life. It differs from a false positive, where nothing is there at all. The finding is genuine, but treating it provides no benefit while carrying the usual risks of treatment. It is invisible in any individual case, because nobody can know that a treated person would have been fine anyway.

What is the difference between sensitivity and specificity?

Sensitivity is how well a test catches people who do have the condition, so high sensitivity means few false negatives. Specificity is how well it clears people who do not, so high specificity means few false positives. The two trade off against each other, and where a test sits on that dial is a deliberate design choice.

Should I worry about one abnormal number on a blood panel?

Not necessarily. Reference ranges are typically set so that a percentage of healthy people fall outside them by definition. On a panel of twenty measurements, at least one result outside its range is the expected outcome rather than a surprise. A trend across several readings is far more informative than a single value.

Most people first hear about clinical trials at a moment when they least want to be researching
anything — after a diagnosis, or while a treatment is not working. The information that turns
up is often either a dense research protocol or a recruitment page that wants your phone number.
Neither explains the thing you actually need to know first: what a trial is, whether you can join
one, and what joining involves.

This is a plain explanation of how clinical trials work in the United States, how eligibility is
decided, and how to check that a study you have found is real. It is information, not medical
advice, and MediVara does not screen, endorse or recommend any specific trial.

What a clinical trial actually is

A clinical trial is a research study in which people volunteer to help answer a specific medical
question — whether a treatment works, how safe it is, or how it compares with existing care.
The key word is research. A trial is not a treatment programme, and it is not a way to get
care that has already been shown to work. It exists because the answer is genuinely not yet known.

That uncertainty is the point, and it is also the main thing to understand before joining one.
If the answer were known, there would be no trial.

The four phases

Drug and device trials are usually described in phases. Each phase is designed to answer a
narrower question in as few participants as possible.

• Phase 1 — a small group. The question is mainly safety and dosage: what
  happens in people, and at what dose.
• Phase 2 — a larger group. Does it appear to work, and what side effects
  show up more clearly at scale?
• Phase 3 — larger still, often across many sites. How does it compare
  with existing standard treatment? This is typically the evidence regulators rely on.
• Phase 4 — after approval. Long-term effects, rarer side effects, and
  performance in wider everyday use.

Not every study fits this ladder. Observational studies, registries and behavioural or screening
studies ask different questions and may involve no new drug at all.

Eligibility: why trials turn people away

Every study publishes eligibility criteria — the requirements a person
must meet to take part. They come in two kinds:

• Inclusion criteria — what you must have. A specific diagnosis, an age
  range, a test result within a certain band.
• Exclusion criteria — what rules you out. Another condition, a medication
  that would interfere, a previous treatment, pregnancy.

Being excluded is not a judgement about you, and it is common. Criteria exist so the study can
answer its question cleanly and so participants are not exposed to avoidable risk. A study of one
condition that admitted people with a second, interacting condition would produce a result nobody
could interpret.

The practical consequence: expect to be screened out of most studies you look at.
People who eventually enrol have usually contacted several.

Informed consent is a process, not a signature

Before you join anything, the study team must take you through informed consent
— learning and discussing the details, including the risks and potential benefits, before you
decide whether to take part. It is the main way people get study information before deciding.

Some things worth knowing about it:

• It is a conversation, and you can take the document away and read it with someone else.
• Signing it does not commit you. You can withdraw from a study at any time, for
  any reason, without giving one.
• If the study changes materially, you should be re-consented.

If a recruiter pushes you to sign quickly, that is a reason to slow down, not to hurry.

Who oversees a study

US studies are reviewed by an Institutional Review Board (IRB) — a group
that reviews, approves and monitors the study protocol, and whose role is to protect the rights
and welfare of participants, including by reviewing the informed consent form. An IRB deliberately
includes people from varying backgrounds, among them a community member, so that review is not
conducted only by researchers.

Separately, ClinicalTrials.gov is the
public registry maintained by the US National Institutes of Health. Under
FDAAA 801 and the
Final Rule, certain trials are legally required to register and to report results — which
is what makes the registry a genuine verification tool rather than an advertising channel.

How to check that a study is real

Many trials recruit through third-party websites and ad campaigns. Some of these are run by
legitimate recruitment firms working for a study sponsor. The site itself is not the study, and
seeing a polished page tells you nothing either way.

A practical verification sequence:

1. Get the NCT number. Every registered study has one, in the form
   NCT followed by eight digits. A legitimate recruiter can give it to you.
2. Look it up on ClinicalTrials.gov directly — type the address yourself
   rather than following a link you were sent.
3. Compare what you were told with the registry record: the condition, the phase,
   the eligibility criteria, the recruiting status and the listed locations.
4. Check who the sponsor is, and whether a site near you is actually recruiting.
5. Ask what happens to your data if you are screened out. A recruitment form is a
   disclosure of health information, and you are entitled to know where it goes.

Warning signs worth taking seriously: no NCT number available on request, a promise of
guaranteed acceptance, a request for payment to participate, pressure to decide immediately, or a
claim that the study will cure a condition. Research does not make guarantees, and legitimate
studies do not charge participants to enrol.

Questions to ask the study team

• What is the purpose of this study, and what phase is it?
• What will I be asked to do, how often, and for how long?
• What are the known risks and side effects so far?
• What tests will I have, and how should I interpret the results?
• Is there a placebo group? If so, what does the placebo group receive — nothing, or
  standard care plus placebo?
• Will I be told which group I am in, and when?
• What happens to my regular treatment while I am enrolled?
• Who pays for what? Research procedures are commonly covered by the sponsor, but routine care
  costs may still be billed — ask specifically.
• Are travel or time costs reimbursed?
• What happens when the study ends? Can I keep taking the treatment if it helped?
• Who do I contact if something goes wrong, at any hour?
• Will the results be shared with me?

For a worked example in one condition, see our guide to asthma clinical trials and how to decide whether to join.

Weighing it up honestly

People join trials for two broad reasons: access to something not otherwise available, and
contributing to knowledge that helps others later. Both are legitimate. Participants also often
receive close monitoring, simply because a study measures things carefully.

Against that: the treatment may not work, you may receive a placebo or the comparison treatment,
there may be side effects that are not yet known, and the schedule of visits and tests is usually
more demanding than ordinary care. A trial is a genuine contribution and a genuine commitment, and
it is reasonable to decline one.

Discuss any trial with the clinician who manages your care before enrolling.
They know your history, your current treatment and how a study schedule would interact with it
— none of which a recruitment form can see.

Sources

• ClinicalTrials.gov — Learn About Studies
• ClinicalTrials.gov — Glossary Terms
• ClinicalTrials.gov — FDAAA 801 and the Final Rule
• About ClinicalTrials.gov

MediVara publishes health journalism. This article is not medical advice, is not reviewed by
a licensed clinician, and MediVara does not screen, endorse or recommend any specific clinical
trial or recruitment service. Decisions about trial participation should be made with a qualified
healthcare professional.